trial
as of 2026-07-01A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
NCTId NCT01143077
at a glance
Phase 3 · Completed
Enrollment 244 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2011-05
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
244 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2010-06
Primary completion
2011-05
Eligibility
ALL · 18 Years
Interventions & indications
Sponsors
Sumitomo Pharmaceuticals AmericaLead Sponsor
Investigators
1
Lurasidone Medical Director, MDStudy Director
Sites
27 total
Little Rock, United StatesEscondido, United StatesGarden Grove, United StatesOakland, United StatesParamount, United StatesPasadena, United StatesPico Rivera, United StatesSan Diego, United StatesSan Diego, United StatesTorrance, United StatesDenver, United StatesAtlanta, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
244
Phase
PHASE3
Primary Completion Date
2011-05
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
investigator